1
|
Chevalier K, de Frémont GM, Roeser A. [Pr Philippe Morlat, Professor in Internal Medicine at Bordeaux University Hospital, medical advisor to the DGOS (Direction générale de l'offre des soins)]. Rev Med Interne 2024:S0248-8663(24)00098-5. [PMID: 38653602 DOI: 10.1016/j.revmed.2024.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2024] [Accepted: 04/04/2024] [Indexed: 04/25/2024]
Affiliation(s)
- K Chevalier
- Service de médecine interne, hôpital Ambroise-Paré-Assistance publique-Hôpitaux de Paris, Boulogne-Billancourt, France.
| | - G M de Frémont
- Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Suède
| | - A Roeser
- Équipe auto-immunité et immunité lymphocytaire B, Institut Necker-Enfants malades, Paris, France
| |
Collapse
|
2
|
Roeser A, Martin de Frémont G, Chevalier K. [New section: "The journal's portraits"]. Rev Med Interne 2024:S0248-8663(24)00090-0. [PMID: 38575439 DOI: 10.1016/j.revmed.2024.03.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/06/2024]
Affiliation(s)
- A Roeser
- Équipe auto-immunité et immunité lymphocytaire B, Institut Necker-Enfants-Malades, 156-160, rue de Vaugirard, 75015 Paris, France.
| | - G Martin de Frémont
- Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Suède
| | - K Chevalier
- Service de médecine interne, hôpital Ambroise-Paré, Assistance publique-Hôpitaux de Paris, Boulogne-Billancourt, France
| |
Collapse
|
3
|
Stammler R, Chevalier K, Benhamida S, Le Goff E, Lebut J, Lau N, Thyrault M, Paulet R. The other great imitator among infectious diseases: Leptospirosis. Rev Med Interne 2024; 45:132-137. [PMID: 38123370 DOI: 10.1016/j.revmed.2023.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2023] [Revised: 11/27/2023] [Accepted: 12/02/2023] [Indexed: 12/23/2023]
Abstract
INTRODUCTION Leptospirosis is a worldwide zoonosis responsible for highly diverse clinical presentations with a wide range of severity. Variable environment exposures to infected urines of rodents have been described. OBSERVATION We report five cases of serologically confirmed leptospirosis leading to hospitalization in an intensive care unit (ICU) of a French center. These patients displayed neurological, respiratory, and abdominal presentation of leptospirosis with variable level of severity. Either professional, leisure related, or daily living exposures have been retrieved. CONCLUSION These cases underline the diversity of clinical presentation and environmental exposure of this infectious disease. They highlight the interest of an exhaustive anamnesis with collection of professional activity, environmental exposures, and leisure activities.
Collapse
Affiliation(s)
- R Stammler
- Intensive care unit, Longjumeau Hospital, Longjumeau, France.
| | - K Chevalier
- Intensive care unit, Longjumeau Hospital, Longjumeau, France
| | - S Benhamida
- Intensive care unit, Longjumeau Hospital, Longjumeau, France
| | - E Le Goff
- Intensive care unit, Longjumeau Hospital, Longjumeau, France
| | - J Lebut
- Intensive care unit, Longjumeau Hospital, Longjumeau, France
| | - N Lau
- Intensive care unit, Longjumeau Hospital, Longjumeau, France
| | - M Thyrault
- Intensive care unit, Longjumeau Hospital, Longjumeau, France
| | - R Paulet
- Intensive care unit, Longjumeau Hospital, Longjumeau, France
| |
Collapse
|
4
|
Grange L, Chevalier K, Azoyan L. [First junior doctors: State of play one year after the implementation of the consolidation phase within the diploma of specialized studies in internal medicine and clinical immunology]. Rev Med Interne 2024; 45:65-68. [PMID: 37993296 DOI: 10.1016/j.revmed.2023.11.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2023] [Revised: 11/01/2023] [Accepted: 11/04/2023] [Indexed: 11/24/2023]
Abstract
INTRODUCTION The 2017 reform of the 3rd cycle of medical studies introduced the concept of supervised autonomy with the creation of a new junior doctor (JD) status. The aim of this work was to interview the first class of JDs in internal medicine and clinical immunology (IMCI) regarding the progress and implementation of this final year of internship. METHODS The IMCI JDs were invited to complete an anonymous online survey, contacted by email and social networks. RESULTS The questionnaire received 36 responses out of an estimated fifty JDs. The majority of JDs spent more than 70% of their time on conventional hospitalisation and less than 20% on scheduled hospitalisation. Most of them would have preferred to do more consultations and provide expert counsels. Weekly working hours were not respected for the majority of JDs. Personal education and academic formation were not respected for 77.8% of JDs. Overall, 75% were satisfied with their empowerment and 88.6% felt that the transition to post residency would be easier with the consolidation phase. A third reported that their residency had confirmed their apprehension about practising as an internist, and even that this apprehension might call into question their future practice. CONCLUSION This survey is an initial assessment of the implementation of the JD year in the IMCI residency. A collective effort around this last year of internship seems to be essential to ensure the personal and professional development of young internists.
Collapse
Affiliation(s)
- L Grange
- Amicale des Jeunes Internistes, 15, rue de l'École-de-Médecine, 75005 Paris, France; Service de médecine interne, CHU de Saint-Étienne, Saint-Étienne, France.
| | - K Chevalier
- Amicale des Jeunes Internistes, 15, rue de l'École-de-Médecine, 75005 Paris, France; Service de médecine interne, CHU Cochin, AP-HP, Paris, France
| | - L Azoyan
- Amicale des Jeunes Internistes, 15, rue de l'École-de-Médecine, 75005 Paris, France; Inserm, Institut Pierre-Louis d'épidémiologie et de santé publique, équipe SUMO, réseau Sentinelles, Sorbonne université, 75012 Paris, France
| |
Collapse
|
5
|
Chevalier K, Thoreau B, Chaigne B, Seror R, Mariette X, Papo T, Sacre K, Lambotte O, Goujard C, Ackermann F, Paule R, Kahn J, Hanslik T, Costedoat-Chalumeau N, Terrier B, Dunogué B, Cohen P, Le Guern V, Hachulla E, Mouthon L. Présentation clinique, évolution et pronostic des patients atteints de connectivite mixte : cohorte rétrospective multicentrique. Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.10.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
6
|
Affiliation(s)
- K Chevalier
- Department of Neurology, Foundation Adolphe de Rothschild Hospital, Paris, France.
| | - G Poillon
- Department of Neuroradiology, Foundation Adolphe de Rothschild Hospital, Paris, France
| |
Collapse
|
7
|
Chevalier K, Genin M, Petit Jean T, Avouac J, Flipo RM, Georgin-Lavialle S, El Mahou S, Pertuiset E, Pham T, Servettaz A, Marotte H, Domont F, Chazerain P, Devaux M, Mekinian A, Sellam J, Fautrel B, Rouzaud D, Ebstein E, Costedoat-Chalumeau N, Richez C, Hachulla E, Mariette X, Seror R. AB1131 IDENTIFICATION OF FACTORS ASSOCIATED WITH THE OCCURRENCE OF SEVERE FORMS OF COVID-19 INFECTION IN PATIENTS WITH AUTOIMMUNE/INFLAMMATORY RHEUMATIC DISEASES. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundPatients with autoimmune/inflammatory rheumatic diseases (AIRD) were suspected to be an at-risk population of severe COVID-19. However, whether this higher risk is linked to the disease or to its treatment is difficult to determine.ObjectivesTo identify, among AIRD patients, factors associated with occurrence of moderate-to-severe COVID19 infection and to evaluate if having an AIRD was associated with an increased risk of severe form of COVID19 infection (defined by hospitalization in ICU or death), compared to general population.MethodsData source: The “Entrepôt des Données de Santé (EDS)” collect data from electronic health records of all patients hospitalized or followed in the AP-HP (39 hospitals in Paris area, France). The French RMD COVID19 cohort is a national multi-center cohort that included patients with confirmed AIRD and diagnosed with COVID-19. All AIRD patients diagnosed with COVID-19 before September 2020 from both cohorts were included.-We Identified factors associated with severe COVID-19 was made in a combined analysis of the 2 cohorts.-Then, we compared COVID-19 infection severity in the EDS-COVID database in AIRD patients and controls, by a propensity score (PS)-matched case-control (1:4) studyResultsAmong 1213 patients (334 in EDS and 879 in RMD cohort), 195 (16.1%) experienced a severe COVID19. In multivariate analysis, greater age, history of interstitial lung disease, arterial hypertension, obesity, sarcoidosis, vasculitis, auto-inflammatory disease and treatment with corticosteroids or rituximab were associated with severe COVID-19 (Table 1).Table 1.AIRD patient’s characteristics associated with severity of COVID-19Patients with mild or moderate infectionPatients with severe infectionOR ajustés 95%CIp-value(N = 1018)(N = 195)Patients characteristics Age55.9 (16.7%)70.3 (14.3%)1.05 [1.03;1.07]<0.001 Gender: Female695 (68.3%)105 (54.1%)0.59 [0.38;0.94]0.025 Interstitial pneumonia38 (3.7%)20 (10.3%)2.94 [1.34;6.34]0.008 Obesity143 (17.8%)38 (27.7%)2.09 [1.26;3.43]0.004 Hypertension268 (26.3%)114 (58.5%)1.81 [1.13;2.89]0.013Underlying Disease: Chronic inflammatory arthritis618 (60.8%)72 (36.9%)Ref. Auto-inflammatory disease29 (2.9%)5 (2.6%)3.91 [1.2;11.32]0.025 Other29 (2.9%)4 (2.1%)0.35 [0.06;1.41]0.15 Connectivitis190 (18.7%)34 (17.4%)1.13 [0.62;2.01]0.69 Sarcoidosis40 (3.9%)24 (12.3%)5.19 [2.15;12.3]<0.001 Vasculitis111 (10.9%)56 (28.7%)1.8 [1.02;3.16]0.044Treatments Corticosteroid318 (31.2%)117 (60.0%)2.47 [1.58;3.87]<0.001 Leflunomide44 (4.3%)2 (1.0%)0.13 [0;0.97]0.045 Rituximab37 (3.7%)22 (11.5%)4.05 [1.96;8.27]<0.001Not significant in multivariate analysisCOPD, Asthma, Coronary heart diseases, stroke, diabetes, smoking, cancer, non-steroidal anti-inflammatory drugs, colchicine, hydroxychloroquine, methotrexate, salazopyrine, mycophenolate mofetil, azathioprine, intravenous immunoglobulins, anti-TNFα, anti-IL1, -IL6, -IL17, Abatacept, JAK inhibitorAmong 35741 COVID-19 patients in EDS, 316 with AIRD were compared to 1264 PS-matched controls. Severe form occurred in 118 (37,3%) AIRD cases and 384 (30.4%) controls (Adjusted OR (aOR) for severe form= 1.43 [1.1;1.9], p=0,01). In analysis restricted to rheumatoid arthritis (RA) and spondylarthritis (SpA), no increased risk of severe form (aOR=1.11 [0.68;1.81]) form or death (aOR=1.00 [0.55;1.81]) was observed.ConclusionIn this multicenter study we confirmed that AIRD patients treated with rituximab or corticosteroids were at increased risk of severe COVID-19, as were those with vasculitis, auto-inflammatory disease, and sarcoidosis. Also, when compared to controls from the same cohort of hospitalized patients, AIRD patients had, overall, an increased risk of severe COVID-19, increased risk not observed in an analysis restricted to patients with RA or SpA.AcknowledgementsFAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributorsPatricia MartelAll clinicians/physicians implicated in COVID-19 patient care in APHP hospital and generated EDS patient dataDisclosure of InterestsNone declared
Collapse
|
8
|
Roeser A, Chevalier K, Azoyan L, Mouthon L. Exercice du droit au remord au sein du Diplôme d’Études Spécialisées de Médecine Interne et Immunologie Clinique : un état des lieux. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.10.150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Chevalier K, Barde F, Benhamida S, Le Meur M, Thyrault M, Bentoumi Y, Lau N, Lebut J. Invasive aspergillosis and endocarditis. Rev Med Interne 2021; 42:678-685. [PMID: 34303547 DOI: 10.1016/j.revmed.2021.07.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2021] [Revised: 05/31/2021] [Accepted: 07/04/2021] [Indexed: 10/20/2022]
Abstract
INTRODUCTION Aspergillusfumigatus can cause a systemic infection called invasive aspergillosis causing pulmonary and extra-pulmonary damage. Aspergillus endocarditis (AE) is a relatively rare disease but can be life-threatening. CASE REPORTS We report here on five cases of endocarditis due to invasive aspergillosis: a 58-year-old man receiving immunosuppressive medication following a kidney graft, a 58-year-old man undergoing chemotherapy for chronic lymphocytic leukaemia, a 55-year-old man receiving corticosteroids for IgA vasculitis, a 52-year-old HIV-infected woman under no specific treatment and a 17-year-old boy under immunosuppressive therapy for auto-immune chronic neutropenia. DISCUSSION Aspergillus accounts for 25-30% of fungal endocarditis and 0.25% to 8.5% of all cases of infectious endocarditis. Aspergillus endocarditis results from invasion of the lung arterioles by hyphae and blood dissemination. It is associated with a very high mortality rate (42-68%). Diagnosing Aspergillus endocarditis is mainly problematic because blood cultures are almost always negative, and fever may be absent. Immunosuppression, haematological malignancies, recent cardiothoracic surgery, negative blood cultures with endocarditis and/or systemic or pulmonary emboli are predictors of AE. In the setting of endocarditis, some clinical characteristics may raise early suspicions of aspergillosis rather than a non-fungal agent: no fever, vegetations affecting the mitral valve, non-valve or aortotomy sites, aortic abscess or pseudo-aneurysm. The identification of invasive aspergillosis is based on a chest CT scan, microscopy/culture or other serological and molecular tests. The treatment of Aspergillus endocarditis requires triazole antifungal drugs, and frequently additional surgical debridement. CONCLUSION Aspergillus endocarditis is rare but is associated with a very high mortality rate. Knowledge of its predictive factors and key clinical features can help to differentiate aspergillosis from non-fungal endocarditis and may enable improved survival rates.
Collapse
Affiliation(s)
- K Chevalier
- Department of Intensive Care Unit, Groupe Hospitalier Nord Essonne, Site Longjumeau, 159, rue du Président François Mitterrand, 91160 Longjumeau, France.
| | - F Barde
- Department of Intensive Care Unit, Groupe Hospitalier Nord Essonne, Site Longjumeau, 159, rue du Président François Mitterrand, 91160 Longjumeau, France
| | - S Benhamida
- Department of Intensive Care Unit, Groupe Hospitalier Nord Essonne, Site Longjumeau, 159, rue du Président François Mitterrand, 91160 Longjumeau, France
| | - M Le Meur
- Department of Intensive Care Unit, Groupe Hospitalier Nord Essonne, Site Longjumeau, 159, rue du Président François Mitterrand, 91160 Longjumeau, France
| | - M Thyrault
- Department of Intensive Care Unit, Groupe Hospitalier Nord Essonne, Site Longjumeau, 159, rue du Président François Mitterrand, 91160 Longjumeau, France
| | - Y Bentoumi
- Department of Intensive Care Unit, Groupe Hospitalier Nord Essonne, Site Longjumeau, 159, rue du Président François Mitterrand, 91160 Longjumeau, France
| | - N Lau
- Department of Intensive Care Unit, Groupe Hospitalier Nord Essonne, Site Longjumeau, 159, rue du Président François Mitterrand, 91160 Longjumeau, France
| | - J Lebut
- Department of Intensive Care Unit, Groupe Hospitalier Nord Essonne, Site Longjumeau, 159, rue du Président François Mitterrand, 91160 Longjumeau, France
| |
Collapse
|
10
|
Chevalier K, Stammler R, Paulet R. [A neurological disorder during pregnancy]. Rev Med Interne 2021; 42:581-582. [PMID: 33648777 DOI: 10.1016/j.revmed.2021.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Revised: 12/26/2020] [Accepted: 02/06/2021] [Indexed: 11/26/2022]
Affiliation(s)
- K Chevalier
- Service de Réanimation, Groupe Hospitalier Nord Essonne-Site Longjumeau, 159, rue du Président François Mitterrand, 91160 Longjumeau, France.
| | - R Stammler
- Service de Réanimation, Groupe Hospitalier Nord Essonne-Site Longjumeau, 159, rue du Président François Mitterrand, 91160 Longjumeau, France
| | - R Paulet
- Service de Réanimation, Groupe Hospitalier Nord Essonne-Site Longjumeau, 159, rue du Président François Mitterrand, 91160 Longjumeau, France
| |
Collapse
|
11
|
Chevalier K, Marie G, Cabon M, Matthias B, Ficko C, Andriamanantena D. Abcès prostatiques à Staphylococcus aureus sécréteur de leucocidine de Panton et Valentine compliqués de localisations secondaires graves : à propos de deux cas. Rev Med Interne 2020. [DOI: 10.1016/j.revmed.2020.10.259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Chevalier K, Justine F, Cabral D, De Laroche M, Hanslik T, Kahn J. Un abcès de prostate non infectieux. Rev Med Interne 2020. [DOI: 10.1016/j.revmed.2020.10.258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
13
|
Chevalier K, Venon MD, Émile JF, Cabral D, Siméon S, Trichet M, Rouveix É, Hanslik T, Coutte L. Une tularémie mimant un lymphome. Rev Med Interne 2020; 41:632-636. [DOI: 10.1016/j.revmed.2020.03.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2019] [Revised: 02/14/2020] [Accepted: 03/06/2020] [Indexed: 10/24/2022]
|
14
|
Chevalier K, Ferreira J, Cabral D, de Laroche M, Hanslik T, Kahn JE. [An abscessed granulomatous prostatitis]. Rev Med Interne 2020; 41:562-566. [PMID: 32674890 DOI: 10.1016/j.revmed.2020.05.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2019] [Revised: 04/13/2020] [Accepted: 05/13/2020] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Prostatic abscesses are usually diagnosed in the setting of bacterial prostatitis. Rarely, they reveal or complicate granulomatous prostatitis. CASE REPORT A 55-year-old man was admitted for acute urinary retention. Urine culture was sterile, with leukocyturia > 106/ml. After failure of antibiotic therapy with cefotaxime, CT scan revealed a necrotic prostatic collection and a nodular non-necrotic tissular lesion in the left upper lung lobe. Trans-rectal drainage of the prostatic lesion and lung biopsies revealed granuloma with multinucleated giant cells (without mycobacteria). The diagnosis of granulomatosis with polyangiitis was confirmed by high level of anti-proteinase 3 antibodies. Treatment with steroids and rituximab resulted in apyrexia, regression of the inflammatory syndrome and clinical manifestations. CONCLUSION The diagnosis of granulomatosis with polyangiitis should be considered in the presence of a non-infectious granulomatous prostatitis with systemic involvement.
Collapse
Affiliation(s)
- K Chevalier
- Service de Médecine Interne, Hôpital Ambroise Paré, Université Paris Saclay, 9 Avenue Charles de Gaulle, 92100 Boulogne-Billancourt, France.
| | - J Ferreira
- Service de Médecine Interne, Hôpital Ambroise Paré, Université Paris Saclay, 9 Avenue Charles de Gaulle, 92100 Boulogne-Billancourt, France
| | - D Cabral
- Service de Radiologie, Hôpital Ambroise Paré, 9 Avenue Charles de Gaulle, 92100 Boulogne-Billancourt, France
| | - M de Laroche
- Service de Médecine Interne, Hôpital Ambroise Paré, Université Paris Saclay, 9 Avenue Charles de Gaulle, 92100 Boulogne-Billancourt, France
| | - T Hanslik
- Service de Médecine Interne, Hôpital Ambroise Paré, Université Paris Saclay, 9 Avenue Charles de Gaulle, 92100 Boulogne-Billancourt, France
| | - J-E Kahn
- Service de Médecine Interne, Hôpital Ambroise Paré, Université Paris Saclay, 9 Avenue Charles de Gaulle, 92100 Boulogne-Billancourt, France
| |
Collapse
|
15
|
Vijayaraghavan S, Lipfert L, Chevalier K, Bushey B, Henley B, Lenhart R, Sendecki J, Beqiri M, Millar H, Packman K, Lorenzi M, Laquerre S, Moores S. B03 JNJ-61186372, an Fc Effector Enhanced EGFR/cMet Bispecific Antibody, Induces EGFR/cMet Downmodulation and Efficacy Through Monocyte and Macrophage Trogocytosis. J Thorac Oncol 2020. [DOI: 10.1016/j.jtho.2019.12.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
16
|
Aubignat M, Chevalier K, Lamy C, Bohbot Y, Delpierre Q, Francois G, Poulet C, Godefroy O. Accidents vasculaires cérébraux multiples révélant une endocardite marastique et un adénocarcinome pulmonaire. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.10.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
17
|
Chevalier K, Venon M, Emile J, Cabral D, Simeon S, Trichet M, Rouveix E, Hanslik T, Coutte L. Fièvre et adénopathies médiastinales : penser aussi à la tularémie. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.10.305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
18
|
Imanbaew D, Nosenko Y, Kerner C, Chevalier K, Rupp F, Riehn C, Thiel W, Diller R. Excited-state dynamics of a ruthenium(II) catalyst studied by transient photofragmentation in gas phase and transient absorption in solution. Chem Phys 2014. [DOI: 10.1016/j.chemphys.2014.03.005] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
19
|
Schmitt Y, Chevalier K, Rupp F, Becherer M, Grün A, Rijs AM, Walz F, Breher F, Diller R, Gerhards M, Klopper W. In-depth exploration of the photophysics of a trinuclear palladium complex. Phys Chem Chem Phys 2014; 16:8332-8. [DOI: 10.1039/c4cp00175c] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
20
|
Wade PR, Palmer JM, McKenney S, Kenigs V, Chevalier K, Moore BA, Mabus JR, Saunders PR, Wallace NH, Schneider CR, Kimball ES, Breslin HJ, He W, Hornby PJ. Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist. Br J Pharmacol 2013; 167:1111-25. [PMID: 22671931 DOI: 10.1111/j.1476-5381.2012.02068.x] [Citation(s) in RCA: 98] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
BACKGROUND & PURPOSE Loperamide is a selective µ opioid receptor agonist acting locally in the gastrointestinal (GI) tract as an effective anti-diarrhoeal but can cause constipation. We tested whether modulating µ opioid receptor agonism with δ opioid receptor antagonism, by combining reference compounds or using a novel compound ('MuDelta'), could normalize GI motility without constipation. EXPERIMENTAL APPROACH MuDelta was characterized in vitro as a potent µ opioid receptor agonist and high-affinity δ opioid receptor antagonist. Reference compounds, MuDelta and loperamide were assessed in the following ex vivo and in vivo experiments: guinea pig intestinal smooth muscle contractility, mouse intestinal epithelial ion transport and upper GI tract transit, entire GI transit or faecal output in novel environment stressed mice, or four weeks after intracolonic mustard oil (post-inflammatory). Colonic δ opioid receptor immunoreactivity was quantified. KEY RESULTS δ Opioid receptor antagonism opposed µ opioid receptor agonist inhibition of intestinal contractility and motility. MuDelta reduced intestinal contractility and inhibited neurogenically-mediated secretion. Very low plasma levels of MuDelta were detected after oral administration. Stress up-regulated δ opioid receptor expression in colonic epithelial cells. In stressed mice, MuDelta normalized GI transit and faecal output to control levels over a wide dose range, whereas loperamide had a narrow dose range. MuDelta and loperamide reduced upper GI transit in the post-inflammatory model. CONCLUSIONS AND IMPLICATIONS MuDelta normalizes, but does not prevent, perturbed GI transit over a wide dose-range in mice. These data support the subsequent assessment of MuDelta in a clinical phase II trial in patients with diarrhoea-predominant irritable bowel syndrome.
Collapse
Affiliation(s)
- P R Wade
- Enterology Research Team, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Spring House, PA 19087, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Rupp F, Chevalier K, Wolf M, Krüger HJ, Wüllen CV, Nosenko Y, Niedner-Schatteburg Y, Riehn C, Diller R. Photoinduced Processes in Cobalt-Complexes: Condensed Phase and Gas Phase. EPJ Web of Conferences 2013. [DOI: 10.1051/epjconf/20134105045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Jin W, Rupp F, Chevalier K, Wolf MMN, Rojas MC, Lefkidis G, Krüger HJ, Diller R, Hübner W. Combined theoretical and experimental study of spin and charge dynamics on the homodinuclear complex [Ni2(II)(L-N4Me2)(emb)]. Phys Rev Lett 2012; 109:267209. [PMID: 23368615 DOI: 10.1103/physrevlett.109.267209] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/24/2012] [Revised: 10/12/2012] [Indexed: 06/01/2023]
Abstract
We present a combined theoretical and experimental study of spin and charge dynamics on the homodinuclear compound [Ni2(II)(L-N4Me2)(emb)]. The theoretically calculated oscillator strengths of the ground-state absorption spectrum show an acceptable agreement with experiment. We predict a local ultrafast laser-induced spin-flip scenario, which involves charge-transfer states. Experimentally, we observe charge dynamics on two different time scales. The two relevant, transient electronic states and their electronic properties are also theoretically characterized. These results provide a joint investigation of the homodinuclear complex and suggest a realistic scenario for ultrafast spin dynamics and other optical-related manipulations.
Collapse
Affiliation(s)
- W Jin
- Department of Physics, University of Kaiserslautern, PO Box 3049, 67653 Kaiserslautern, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Wade PR, Palmer JM, Mabus J, Saunders PR, Prouty S, Chevalier K, Gareau MG, McKenney S, Hornby PJ. Prokineticin-1 evokes secretory and contractile activity in rat small intestine. Neurogastroenterol Motil 2010; 22:e152-61. [PMID: 19930539 DOI: 10.1111/j.1365-2982.2009.01426.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
BACKGROUND Prokineticins 1 and 2 (PROK1 and PROK2) are so named because they contract gastrointestinal smooth muscle, yet little else is known about their role in gastrointestinal function. Therefore, we used a combination of approaches to elucidate the mechanisms by which PROK1 alters ileal contractility and secretion in rats. METHODS RT-PCR and immunofluorescence were used to determine PROK and receptor (PK-R) mRNA levels and PK-R1 localization, respectively. Upper GI transit and fluid secretion were determined in vivo. Contractility and intestinal epithelial ion transport were assessed in isolated ileal segments. KEY RESULTS In the gastric fundus, PROK1 mRNA is highly expressed (70-fold >PROK2 mRNA) whereas the ileum has the highest mRNA expression of its receptor. PK-R1 immunoreactivity is visualized in ileal crypt cells, and in submucosal and myenteric neurons. In ileal segments, PROK1 evokes biphasic contractile responses consisting of an early, TTX-sensitive response (EC(50) = 87.8 nmol L(-1)) followed by a late, TTX-insensitive (EC(50) = 72.4 nmol L(-1)) component that is abolished in mucosa-free preparations. Oral administration of PROK1 enhances small bowel transit (111 +/- 3% of control) and fluid secretion (340 +/- 90% of control) and in muscle-stripped ileal preparations increases short-circuit current (EC(50) = 8.2 nmol L(-1)) in a TTX-insensitive manner. The PROK1-evoked Cl- secretion is reduced by piroxicam (non-selective cyclooxygenase inhibitor), and a prostaglandin EP(4) receptor antagonist (AH23848), but not a thromboxane receptor antagonist (GR32191B). CONCLUSIONS & INFERENCES These results demonstrate that PROK1 has oral prokinetic and secretogogue activity and that it acts on the intestinal mucosa via PK-R1 and prostaglandin receptors to mediate these effects.
Collapse
Affiliation(s)
- P R Wade
- Enterology Research Team, Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, LLC, Spring House, PA, USA
| | | | | | | | | | | | | | | | | |
Collapse
|